{
    "title": "CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer",
    "pmid": "23476897",
    "pmcid": "PMC3584248",
    "study_parameters": [
        {
            "Study Parameters ID": 1444930473,
            "Variant Annotation ID": 1444930388,
            "Study Type": "clinical trial",
            "Study Cases": 224.0,
            "Study Controls": null,
            "Characteristics": "endpoint: endoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.0001 for trend: normal > intermediate > slow",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1444930388"
        },
        {
            "Study Parameters ID": 1444930499,
            "Variant Annotation ID": 1444930474,
            "Study Type": "clinical trial",
            "Study Cases": 224.0,
            "Study Controls": null,
            "Characteristics": "endpoint: N-desmethyltamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.06 for trend: normal > intermediate > slow",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.06",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1444930474"
        },
        {
            "Study Parameters ID": 1444930497,
            "Variant Annotation ID": 1444930474,
            "Study Type": "clinical trial",
            "Study Cases": 224.0,
            "Study Controls": null,
            "Characteristics": "endpoint: 4-hydroxytamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.13 for trend: normal > intermediate > slow",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.13",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1444930474"
        },
        {
            "Study Parameters ID": 1444930476,
            "Variant Annotation ID": 1444930474,
            "Study Type": "clinical trial",
            "Study Cases": 224.0,
            "Study Controls": null,
            "Characteristics": "endpoint: tamoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.39 for trend: normal > intermediate > slow",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.39",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1444930474"
        }
    ],
    "var_drug_ann": [
        {
            "Variant Annotation ID": 1444930388,
            "Variant/Haplotypes": "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "endoxifen",
            "PMID": 23476897,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes] An additional nested case-control study (n=48) showed an  increased risk of recurrence at low and high (>70 ng/ml) endoxifen concentrations.",
            "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
            "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "concentrations of",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23476897",
            "Variant Annotation ID_norm": "1444930388"
        },
        {
            "Variant Annotation ID": 1444930474,
            "Variant/Haplotypes": "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
            "PMID": 23476897,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "no",
            "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
            "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
            "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "concentrations of",
            "Multiple drugs And/or": "and",
            "Population types": "in women with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23476897",
            "Variant Annotation ID_norm": "1444930474"
        }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
}